Mergers & Acquisitions ·
Theravance Biopharma filed this 8-K to voluntarily supplement its definitive proxy statement regarding the proposed…
TBPHTheravance Biopharma, Inc.
Theravance Biopharma filed this 8-K to voluntarily supplement its definitive proxy statement regarding the proposed merger with Zymeworks. The filing discloses supplemental information in response to three shareholder complaints and thirteen demand letters alleging disclosure deficiencies. Key updates include details on the sale process, noting that Lazard contacted eighteen potential counterparties between February and March 2025, resulting in confidentiality agreements with twelve parties. The Company received bids from three parties, including GlaxoSmithKline. Additionally, the filing confirms Evercore will receive a $7 million fee upon merger consummation and clarifies that no post-closing employment terms have been discussed for management. Theravance Biopharma operates in the biotechnology industry, focusing on the development of treatments for respiratory diseases.